Meridia, Reductil, SCOUT, obesity

Links shared publicly online about this topic.

  • 1,581
    total visits

Meridia, Reductil, SCOUT, obesity

theheart.org

An early analysis for the randomized placebo-controlled trial's primary end point, a composite of cardiovascular events, found a

View full resource at theheart.org

Tags: Obesity, FDA

  • Share

Most Recently Shared on November 23, 2009 at 7:35 pm By:

theheartorg Shelley Wood

FDA reports apparent excess of CV events with sibutramine in SCOUT http://bit.ly/5vUpGx #heartwire

2 years ago...

Sibutramine Health Risks Will Limit Drug's Use: Meridia Cardiovascular Side Effects Evoke Obesity Drug Label Upgrade

weightloss.suite101.com — “Sibutramine health risks revealed by SCOUT study evoke FDA safety review. Raised cardiovascular side effects for obesity drug force Meridia label upgrade for heart risk.View full resource at weightloss.suite101.com

  • View Related
  • Share

Most Recently Shared on January 28, 2010 at 10:23 am By:

HealthPassion HealthPassion Health News

Sibutramine Health Risks Will Limit Drug's Use: Sibutramine health risks revealed by the SCOUT study evoke FDA saf... http://bit.ly/brq8wU

2 years ago...

Anti-Obesity Drug Banned In Europe

medicalnewstoday.com — “The European Medicines Agency (EMEA) has recommended that the appetite suppressant sibutramine, also known as Reductil, should no longer be prescribed by doctors and that pharmacists should no lonView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on January 24, 2010 at 10:00 am By:

medical_tweets medical_tweets Health News

Anti-Obesity Drug Banned In Europe The European Medicines Agency (EMEA) has recommended that the appetite suppressant.. http://bit.ly/8TmQ7R

2 years ago...

Advertisement